Cediranib

Generic Name: Cediranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇FN_₄O_₃

CAS Number: 288383-20-0

Unique Ingredient Identifier: NQU9IPY4K9

Background: The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Indication: For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma

Phase 1

Completed

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Childhood Diffuse Large Cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Childhood Burkitt Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma

Interventions: Biological: bevacizumab
Drug: cediranib maleate

First Posted Date: 2007-04-11

Last Posted Date: 2014-02-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00458731

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Recurrent Laryngeal Verrucous Carcinoma
Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Salivary Gland Squamous Cell Carcinoma
Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
Stage IV Hypopharyngeal Squamous Cell Carcinoma
Stage IV Laryngeal Squamous Cell Carcinoma
Stage IV Laryngeal Verrucous Carcinoma
Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
Stage IV Major Salivary Gland Carcinoma
Recurrent Laryngeal Squamous Cell Carcinoma

Interventions: Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis

First Posted Date: 2007-04-11

Last Posted Date: 2015-05-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT00458978

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

AZD2171 to Treat Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Procedure: Magnetic Resonance Imaging (DCE-MRI)
Drug: AZD2171
Drug: Prednisone

First Posted Date: 2007-02-19

Last Posted Date: 2018-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 59

Registration Number: NCT00436956

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer

Phase 2

Terminated

Conditions: Adult Primary Hepatocellular Carcinoma
Advanced Adult Primary Liver Cancer
Localized Unresectable Adult Primary Liver Cancer
Recurrent Adult Primary Liver Cancer

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis
Procedure: computed tomography
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Other: pharmacological study

First Posted Date: 2007-01-29

Last Posted Date: 2016-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00427973

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer

Interventions: Drug: cediranib maleate
Drug: pemetrexed disodium

First Posted Date: 2006-12-13

Last Posted Date: 2018-04-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00410904

Locations: 🇺🇸
Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States

AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors

Phase 1

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Recurrent Childhood Subependymal Giant Cell Astrocytoma
Childhood Grade II Meningioma
Childhood Infratentorial Ependymoma
Childhood Spinal Cord Neoplasm
Recurrent Childhood Brain Stem Glioma
Recurrent Childhood Cerebellar Astrocytoma
Recurrent Childhood Ependymoma
Recurrent Childhood Medulloblastoma
Childhood Cerebral Astrocytoma

Interventions: Drug: Cediranib Maleate

First Posted Date: 2006-05-17

Last Posted Date: 2016-03-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT00326664

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 8 locations

AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Phase 2

Terminated

Conditions: Spinal Cord Neurofibroma
Plexiform Neurofibroma
Neurofibromatosis Type 1

Interventions: Drug: Cediranib Maleate

First Posted Date: 2006-05-17

Last Posted Date: 2017-08-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 26

Registration Number: NCT00326872

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Howard University Hospital, Washington, D.C., District of Columbia, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2006-05-04

Last Posted Date: 2013-01-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT00321724

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

First Posted Date: 2006-04-03

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00310089

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Epithelial Mesothelioma
Localized Malignant Mesothelioma
Sarcomatous Mesothelioma
Advanced Malignant Mesothelioma
Recurrent Malignant Mesothelioma

Interventions: Drug: cediranib maleate

First Posted Date: 2006-04-03

Last Posted Date: 2014-07-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00309946

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy